Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bradykinin receptor B2 | Starlite/ChEMBL | References |
Cavia porcellus | Bradykinin B2 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Onchocerca volvulus | Bradykinin B2 receptor | 372 aa | 383 aa | 20.9 % | |
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | bradykinin receptor B2 | 391 aa | 354 aa | 19.2 % |
Echinococcus multilocularis | neuropeptide receptor | Bradykinin B2 receptor | 372 aa | 305 aa | 24.6 % |
Loa Loa (eye worm) | neuropeptide F receptor | Bradykinin B2 receptor | 372 aa | 355 aa | 21.4 % |
Brugia malayi | putative neuropeptide receptor NPR1 | Bradykinin B2 receptor | 372 aa | 312 aa | 24.0 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Bradykinin B2 receptor | 372 aa | 335 aa | 22.7 % |
Schistosoma japonicum | Rhodopsin, putative | Bradykinin B2 receptor | 372 aa | 323 aa | 20.4 % |
Onchocerca volvulus | Bradykinin B2 receptor | 372 aa | 323 aa | 20.7 % | |
Onchocerca volvulus | Bradykinin B2 receptor | 372 aa | 305 aa | 24.3 % | |
Schistosoma mansoni | biogenic amine (octopamine/dopamine) receptor | Bradykinin B2 receptor | 372 aa | 326 aa | 22.7 % |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Bradykinin B2 receptor | 372 aa | 313 aa | 19.2 % |
Schistosoma mansoni | adenoreceptor | Bradykinin B2 receptor | 372 aa | 361 aa | 21.1 % |
Loa Loa (eye worm) | hypothetical protein | Bradykinin B2 receptor | 372 aa | 311 aa | 23.5 % |
Echinococcus granulosus | neuropeptide receptor | Bradykinin B2 receptor | 372 aa | 338 aa | 24.0 % |
Schistosoma mansoni | peptide (allatostatin)-like receptor | Bradykinin B2 receptor | 372 aa | 337 aa | 25.5 % |
Onchocerca volvulus | Mitochondrial inner membrane protein homolog | Bradykinin B2 receptor | 372 aa | 339 aa | 23.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.248 | 0.5 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.248 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.248 | 0.5 | 0.5 |
Loa Loa (eye worm) | inward rectifying k channel family protein 1 | 0.248 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1100 nM | Concentration required to inhibit specific binding of [ 3H]BK (0.06 nM) to Bradykinin receptor B2 in guinea pig ileum membrane preparations by 50%. | ChEMBL. | 9767643 |
IC50 (binding) | = 1100 nM | In vitro inhibitory activity towards bradykinin receptor B2 using [3H]-BK (0.06 nM) as a radioligand in guinea pig ileum membrane preparation | ChEMBL. | 15027853 |
IC50 (binding) | = 1100 nM | Concentration required to inhibit specific binding of [ 3H]BK (0.06 nM) to Bradykinin receptor B2 in guinea pig ileum membrane preparations by 50%. | ChEMBL. | 9767643 |
IC50 (binding) | = 1100 nM | In vitro inhibitory activity towards bradykinin receptor B2 using [3H]-BK (0.06 nM) as a radioligand in guinea pig ileum membrane preparation | ChEMBL. | 15027853 |
IC50 (binding) | = 8400 nM | Inhibition specific binding of [3H]-BK (1.0 nM) to human Bradykinin receptor B2 which was expressed in CHO (Chinese hamster ovary) cells by 50%. | ChEMBL. | 9767643 |
IC50 (binding) | = 8400 nM | In vitro inhibitory activity towards human bradykinin receptor B2 expressed in CHO cells using [3H]-BK (1.0 nM) as a radioligand | ChEMBL. | 15027853 |
IC50 (binding) | = 8400 nM | Inhibition specific binding of [3H]-BK (1.0 nM) to human Bradykinin receptor B2 which was expressed in CHO (Chinese hamster ovary) cells by 50%. | ChEMBL. | 9767643 |
IC50 (binding) | = 8400 nM | In vitro inhibitory activity towards human bradykinin receptor B2 expressed in CHO cells using [3H]-BK (1.0 nM) as a radioligand | ChEMBL. | 15027853 |
Inhibition (functional) | 0 % | Compound tested in vivo for inhibition of Bradykinin induced Bronchoconstriction in anaesthetized guinea pig at 1mg/kg,po; ;NT=Not tested | ChEMBL. | 9767643 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.